From memory the performance hurdles are share price, clinical progress and commercial (presumably partnership/outright sale).
I was pleasantly surprised that the options expired since I assumed the clinical progress would be a soft ball target.
Ann: Change of Director's Interest Notice, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
